New mRNA flu vaccine shows promise in early human trials
NCT ID NCT06382311
First seen Feb 05, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tested a new mRNA-based vaccine designed to protect against a potential H5 influenza (bird flu) pandemic. Nearly 1,000 healthy adults aged 18 to 85 received different doses to find the safest and most effective one. Researchers monitored side effects like pain, fever, and fatigue, and measured the immune response. The goal is to have a ready vaccine if a pandemic strikes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Anniston, Alabama, 36207, United States
-
GSK Investigational Site
Little Rock, Arkansas, 72204, United States
-
GSK Investigational Site
Fort Collins, Colorado, 80525, United States
-
GSK Investigational Site
Fort Myers, Florida, 33912, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33409, United States
-
GSK Investigational Site
Chamblee, Georgia, 30043, United States
-
GSK Investigational Site
El Dorado, Kansas, 67042, United States
-
GSK Investigational Site
Lenexa, Kansas, 66219, United States
-
GSK Investigational Site
Lexington, Kentucky, 40509, United States
-
GSK Investigational Site
Kansas City, Missouri, 64114, United States
-
GSK Investigational Site
Omaha, Nebraska, 68144, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89102, United States
-
GSK Investigational Site
Rochester, New York, 14609, United States
-
GSK Investigational Site
Greensboro, North Carolina, 27405, United States
-
GSK Investigational Site
Winston-Salem, North Carolina, 27103, United States
-
GSK Investigational Site
Edmond, Oklahoma, 73013, United States
-
GSK Investigational Site
Yukon, Oklahoma, 73099, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19111, United States
-
GSK Investigational Site
Austin, Texas, 78705, United States
-
GSK Investigational Site
Norfolk, Virginia, 23502, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States
Conditions
Explore the condition pages connected to this study.